Table 3 One-year outcomes

From: Mechanisms underlying superior outcomes of transcatheter aortic valve implantation with the latest balloon expandable valve

 

Overall

Small (20 mm or 23 mm)

Large (26 mm or 29 mm)

 

Matched cohort

S3UR

S3

 

S3UR

S3

 

S3UR

S3

 
  

p

  

p

  

p

Left ventricular ejection fraction, %

63.4 ± 8.1

63.2 ± 9.3

0.429

65.2 ± 6.6

64.9 ± 7.8

0.782

60.8 ± 9.4

60.6 ± 10.8

0.285

Effective orifice area, cm²

1.70 ± 0.45

1.56 ± 0.44

<0.001

1.53 ± 0.39

1.41 ± 0.35

<0.001

1.97 ± 0.42

1.80 ± 0.47

<0.001

Index effective orifice area, cm²/m²

1.15 ± 0.32

1.06 ± 0.30

<0.001

1.09 ± 0.33

1.00 ± 0.27

<0.001

1.24 ± 0.29

1.13 ± 0.32

<0.001

Peak flow velocity, m/s

2.3 ± 0.48

2.4 ± 0.48

<0.001

2.4 ± 0.48

2.5 ± 0.47

<0.001

2.0 ± 0.40

2.2 ± 0.41

<0.001

Mean pressure gradient, mmHg

11.1 ± 5.5

12.5 ± 5.5

<0.001

12.5 ± 5.9

14.0 ± 5.7

<0.001

8.8 ± 3.8

10.1 ± 4.2

<0.001

Mean pressure gradient ≥20 mmHg

25 (3.2)

52 (6.7)

0.006

22 (6.6)

47 (14.2)

0.007

3 (1.4)

5 (2.2)

0.237

Prosthesis-patient mismatch

none

439 (85.9)

403 (75.5)

<0.001

261 (82.1)

229 (70.5)

0.003

178 (92.2)

174 (83.3)

0.006

moderate

59 (11.5)

101 (18.9)

 

44 (13.8)

73 (22.5)

 

15 (7.8)

28 (13.4)

 

severe

13 (2.5)

30 (5.6)

 

13 (4.1)

23 (7.1)

 

0 (0)

7 (3.3)

 

Paravalvular leakage ≥ mild

142 (27.1)

184 (33.9)

0.032

99 (30.7)

123 (37.2)

0.199

43 (21.3)

61 (28.6)

0.093

Increased paravalvular leakage

143 (27.3)

174 (32.2)

0.086

95 (29.5)

121 (36.7)

0.052

48 (23.9)

53 (25.1)

0.770

Mitral regurgitation ≥moderate

41 (7.8)

42 (7.7)

0.711

26 (7.9)

29 (8.8)

0.925

15 (7.5)

13 (6.1)

0.314

Tricuspid regurgitation ≥moderate

51 (9.6)

52 (9.6)

0.711

27 (8.3)

34 (10.2)

0.679

24 (11.9)

18 (8.5)

0.241

NYHA III or IV

5 (1.0)

14 (2.7)

0.040

4 (1.3)

8 (2.5)

0.248

1 (0.5)

6 (2.9)

0.061

Brain Natrium Peptide, pg/ml

93 [46-189]

111 [52–253]

0.040

94 [46–187]

118 [57–264]

0.018

93 [47–211]

101 [48–237]

0.706

  1. Data are depicted as means with standard deviations ( ± SD) or counts with percentages (%).
  2. S3UR SAPIEN 3 Ultra RESILIA, S3 SAPIEN 3, NYHA New York Heart Association.
  3. P-values are from Fisher’s test (2 × 2 comparison), chi-squared test (n x 2 comparisons), or t-tests (continuous parameters).
Back to article page